DRE and Prostate Cancer

Friday 27th March 2020

A digital rectal examination (DRE) is a useful screening tool, which can be used in conjunction with a PSA test, to help determine if a patient should be referred on a prostate cancer pathway. Prostate cancers may not necessarily secrete PSA; and so a PSA alone may be falsely reassuring. Thus, a DRE can form an important part of the prostate cancer investigation process.

The examination:

All practitioners should be able to perform a DRE, as the prostate is positioned close to the anal vert, therefore the length of fingers do not restrict the examination. During a DRE, practitioners should assess the prostate to see if it is significantly:

Jagged
Hard
Irregular, as opposed to smooth.

 

Find out more:

Access GatewayC’s course ‘Prostate Cancer – Responding to a PSA Screening Request’ and collect up to 2 hours of CPD here.

Access this BMJ learning module here

Keep up to date: Twitter | Facebook | LinkedIn

Latest from the Blog

Meet the specialists: headache or brain tumour Q&A

Meet the specialists: headache or brain tumour Q&A

23rd March 2021 Missed our free GatewayC Live webinar? Watch our recording here. In this webinar, GatewayC met Dr Catherine McBain, Consultant Clinical Oncologist at The Christie NHS Foundation Trust and Dr Rajiv Mohanraj, Consultant Neurologist at the Greater...

read more

Related Posts

Meet the specialists: headache or brain tumour Q&A

Meet the specialists: headache or brain tumour Q&A

23rd March 2021 Missed our free GatewayC Live webinar? Watch our recording here. In this webinar, GatewayC met Dr Catherine McBain, Consultant Clinical Oncologist at The Christie NHS Foundation Trust and Dr Rajiv Mohanraj, Consultant Neurologist at the Greater...

read more
NEW COURSE LIVE: Breast Cancer Recurrence

NEW COURSE LIVE: Breast Cancer Recurrence

Thursday 25th March 2021 We are delighted to announce that the new Breast Cancer Recurrence course is available on GatewayC. There are an estimated 35,000 people living with secondary breast cancer in the UK. Breast cancers most commonly recur in the first 2-3 years...

read more